Morgan Stanley Synaptogenix, Inc. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Synaptogenix, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,287 shares of SNPX stock, worth $9,193. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,287
Previous 2,287
-0.0%
Holding current value
$9,193
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SNPX
# of Institutions
25Shares Held
955KCall Options Held
0Put Options Held
0-
Jim Simons Renaissance Technologies LLC | New York, Ny401KShares$1.61 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA154KShares$620,9730.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il83.5KShares$335,8460.0% of portfolio
-
Two Sigma Securities, LLC New York, NY83.4KShares$335,3040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA68.5KShares$275,4580.0% of portfolio
About Synaptogenix, Inc.
- Ticker SNPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 6,840,630
- Market Cap $27.5M
- Description
- Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...